Search Results

Displaying Results 26-41 of 41 "'PFE'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.

Mar 19, 2026, 06:00 ET Canadian Solar Reports Fourth Quarter and Full Year 2025 Results

module shipments in the U.S. are expected to be slightly lower in 2026 than in 2025, primarily due to a limited supply of solar cells qualified as non-PFE under the OBBBA in the first half of the year. The high cost of such cells will also affect our profitability. I believe this is temporary, as our own

More news about: Canadian Solar Inc.

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 04, 2026, 08:55 ET NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Markets and the New York Rangers, celebrates the 32nd Annual Skate with the Greats.Closing BellPfizer (NYSE: PFE) rings the NYSE Closing BellFor market insights, IPO activity, and today's opening bell, download the NYSE TV App:

More news about: New York Stock Exchange

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

J-Pharma, OHARA Pharmaceutical (TYO: 5218), Compass Therapeutics (NASDAQ: CMPX), Merck (NYSE: MRK), Eisai (TYO: 4523), Seagen (NASDAQ: SGEN), Pfizer (NYSE: PFE), Bold Therapeutics (NASDAQ: BOLD), Senhwa Biosciences, Virogin Biotech, Replimune (NASDAQ: REPL), Bayer (ETR: BAYN), RedHill Biopharma (NASDAQ: RDHL),

More news about: DelveInsight Business Research, LLP

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

Feb 24, 2026, 09:35 ET Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

(Cboe CA: HELP), Takeda Pharmaceutical Company Limited (NYSE: TAK) and Compass Pathways plc (NASDAQ: CMPS), Pfizer Inc. (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY).

More news about: Market News Updates

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

Feb 19, 2026, 17:31 ET Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

Pharmaceuticals, Dren Bio, Nektar Therapeutics (NASDAQ: NKTR), Eli Lilly and Company (NYSE: LLY), Incyte Corporation (NASDAQ: INCY), Pfizer (NYSE: PFE), Sun Pharmaceuticals (NSE: SUNPHARMA), and othersKey

More news about: DelveInsight Business Research, LLP

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

Feb 17, 2026, 17:31 ET Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

ABBV), Sanofi (EPA: SAN), Regeneron Pharmaceuticals (NASDAQ: REGN), Janssen Pharmaceutical, Eli Lilly (NYSE: LLY), Sobi (STO: SOBI), Pfizer (NYSE: PFE), and othersKey Juvenile Idiopathic

More news about: DelveInsight Business Research, LLP

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

Feb 16, 2026, 17:31 ET Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

Almirall (BME: ALM), Organon (NYSE: OGN), Torii Pharmaceutical, Chugai Pharmaceutical (TYO: 4519), Galderma, Maruho, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), Regeneron Pharmaceuticals (NASDAQ: REGN), Incyte (NASDAQ: INCY), Japan Tobacco (TYO: 2914), Otsuka Pharmaceutical, Medimetriks Pharmaceuticals, Acrotech

More news about: DelveInsight Business Research, LLP

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

Pharmaceutical (SHA: 688192), Daiichi Sankyo (TYO: 4568), AstraZeneca (LON: AZN), Jiangsu Hansoh Pharmaceutical, Boehringer Ingelheim, Pfizer (NYSE: PFE), Johnson & Johnson Innovative Medicine (NYSE: JNJ), Yuhan Corporation (KRX: 000100), Eli Lilly and Company (NYSE: LLY), and others

More news about: DelveInsight Business Research, LLP

PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

early-stage breast cancer do not go on to develop metastatic disease.Leading PROTAC companies, such as Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others, are developing novel PROTAC that can be available in the

More news about: DelveInsight Business Research LLP

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

Jan 30, 2026, 10:19 ET $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ: ONCY), Pfizer (NYSE: PFE), Verastem Oncology (NASDAQ: VSTM), Perspective Therapeutics (NYSE-A: CATX), and RenovoRx (NASDAQ: RNXT) directly at the intersection

More news about: USA News Group

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec. 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab

More news about: Astellas Pharma Inc.

Dec 09, 2025, 06:55 ET Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for

More news about: Fosun Pharma

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

Oct 27, 2025, 08:30 ET Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)

More news about: NetworkNewsWire

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin),

More news about: Astellas Pharma Inc.

Precision Oncology Approaches Drive $312B Market Transformation

Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation

Therapeutics, Inc. (NASDAQ: NRIX), GRAIL, Inc. (NASDAQ: GRAL), C4 Therapeutics, Inc. (NASDAQ: CCCC), and Pfizer, Inc. (NYSE: PFE).

More news about: USA News Group

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.